Aikium

Curated by Signal

Developer of protein therapeutics for neuro-inflammation and oncology

Overview

Developer of protein therapeutics for neuro-inflammation and oncology. The company leverages breakthroughs in synthetic biology and deep learning to develop proprietary non-antibody scaffold proteins called SeqR, which bind to disordered regions of target proteins in a sequence-specific manner.

Key facts

Founded: 2022
Headquarters: Berkeley, United States
Stage: Sign up to view
Industry: Life Sciences Technology

More on Vanberra Signal

Members only

Business overviewCore metrics and financials PeopleLeadership and key people Similar companiesPeers and competitors Deep AnalysisAI-generated strategic report

Competitors & similar companies

More Life Sciences Technology companies

ACS Diagnostics
Provider of ECG monitoring device
Life Sciences TechnologyIrvine, United States
OvaTel
Provider of microscope designed to allow a woman to check her fertility
Life Sciences TechnologyBoca Raton, United States
Nudge
Provider of dietary supplements for irritable bowel syndrome
Life Sciences TechnologyLos Angeles, United States

About Aikium

What does Aikium do?

Developer of protein therapeutics for neuro-inflammation and oncology.

Where is Aikium headquartered?

Aikium is headquartered in Berkeley, United States.

When was Aikium founded?

Aikium was founded in 2022.

Which sector is Aikium in?

Aikium operates in Life Sciences Technology.

Who are Aikium's competitors?

Companies similar to Aikium include ACS Diagnostics, OvaTel, and Nudge.